InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability (2022 - 2025)

InMed Pharmaceuticals' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $20000.0 for Q2 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $20000.0 in Q2 2025; TTM through Jun 2025 was $20000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $20000.0, changed N/A from the prior year.
• Non-Current Deferred Tax Liability slipped to $20000.0 in Q2 2025 per INM's latest filing, from $119889.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $119889.0 in Q2 2023 and bottomed at $16546.0 in Q2 2022.
• The 3-year median for Non-Current Deferred Tax Liability is $20000.0 (2025), against an average of $52145.0.
• Biggest YoY gain for Non-Current Deferred Tax Liability was 624.58% in 2023; the steepest drop was 624.58% in 2023.
• Year by year, Non-Current Deferred Tax Liability stood at $16546.0 in 2022, then soared by 624.58% to $119889.0 in 2023, then plunged by 83.32% to $20000.0 in 2025.
• Per Business Quant, the three latest INM Non-Current Deferred Tax Liability figures stand at $20000.0 (Q2 2025), $119889.0 (Q2 2023), and $16546.0 (Q2 2022).